JAK inhibitors: Treatment efficacy and safety profile in patients with psoriasis

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Hsu, Leeyen ^a   Armstrong, April W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; PLACEBO; RUXOLITINIB; STAT PROTEIN; TOFACITINIB; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MOLECULAR TARGETED THERAPY; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRAZOLES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84901745073     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/283617     Document Type: Review

References (51)

1. Rachakonda T. D., Schupp C. W., Armstrong A. W., Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology 2014 70 3 512 516
2. Armstrong A. W., Harskamp C. T., Ledo L., Rogers J. H., Armstrong E. J., Coronary artery disease in patients with psoriasis referred for coronary angiography. The American Journal of Cardiology 2012 109 7 976 980 2-s2.0-84858750389 10.1016/j.amjcard.2011.11.025
3. Greaves M. W., Weinstein G. D., Treatment of psoriasis. The New England Journal of Medicine 1995 332 9 581 588 2-s2.0-0028968022 10.1056/ NEJM199503023320907
4. Kurd S. K., Gelfand J. M., The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. Journal of the American Academy of Dermatology 2009 60 2 218 224 2-s2.0-58149336900 10.1016/j.jaad.2008.09.022
5. Griffiths T. W., Griffiths C. E. M., Voorhees J. J., Immunopathogenesis and immunotherapy of psoriasis. Dermatologic Clinics 1995 13 4 739 749 2-s2.0-0028812644
6. Kimball A. B., Gordon K. B., Fakharzadeh S., Yeilding N., Szapary P. O., Schenkel B., Guzzo C., Li S., Papp K. A., Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. British Journal of Dermatology 2012 166 4 861 872 2-s2.0-84859118948 10.1111/j.1365-2133.2012.10901.x
7. Menter A., Tyring S. K., Gordon K., Kimball A. B., Leonardi C. L., Langley R. G., Strober B. E., Kaul M., Gu Y., Okun M., Papp K., Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. Journal of the American Academy of Dermatology 2008 58 1 106 115 2-s2.0-37349003068 10.1016/j.jaad.2007.09.010 (Pubitemid 350298146)
8. Papp K. A., Tyring S., Lahfa M., Prinz J., Griffiths C. E. M., Nakanishi A. M., Zitnik R., Van De Kerkhof P. C. M., A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. British Journal of Dermatology 2005 152 6 1304 1312 2-s2.0-21644481166 10.1111/j.1365-2133.2005.06688.x (Pubitemid 40933433)
9. Reich K., Nestle F. O., Papp K., Ortonne J.-P., Evans R., Guzzo C., Li S., Dooley L. T., Griffiths C. E. M., Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet 2005 366 9494 1367 1374 2-s2.0-26644433889 10.1016/S0140-6736(05)67566-6 (Pubitemid 41443403)
10. Hirahara K., Ghoreschi K., Laurence A., Yang X.-P., Kanno Y., O'Shea J. J., Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine and Growth Factor Reviews 2010 21 6 425 434 2-s2.0-78649689761 10.1016/j.cytogfr.2010.10.006
11. Mak R. K. H., Hundhausen C., Nestle F. O., Progress in understanding the immunopathogenesis of psoriasis. Actas Dermo-Sifiliograficas 2009 100 supplement 2 2 13 2-s2.0-76749141832 10.1016/S0001-7310(09)73372-1
12. Nestle F. O., Kaplan D. H., Barker J., Mechanisms of disease: psoriasis. The New England Journal of Medicine 2009 361 5 444 509 2-s2.0-68049131637 10.1056/NEJMra0804595
13. Nickoloff B. J., The cytokine network in psoriasis. Archives of Dermatology 1991 127 6 871 884 2-s2.0-0025831330 10.1001/archderm.127.6.871
14. Nickoloff B. J., Cracking the cytokine code in psoriasis. Nature Medicine 2007 13 3 242 244 2-s2.0-33847757147 10.1038/nm0307-242 (Pubitemid 46376653)
15. Sawyers C. L., Chronic myeloid leukemia. The New England Journal of Medicine 1999 340 17 1330 1340 2-s2.0-0033614446 10.1056/NEJM199904293401706 (Pubitemid 29196596)
16. Chang B. Y., Zhao F., He X., Ren H., Braselmann S., Taylor V., Wicks J., Payan D. G., Grossbard E. B., Pine P. R., Bullard D. C., JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. Journal of Immunology 2009 183 3 2183 2192 2-s2.0-68149182278 10.4049/jimmunol.0804063
17. Murray P. J., The JAK-STAT signaling pathway: input and output integration. Journal of Immunology 2007 178 5 2623 2629 2-s2.0-33847351136 (Pubitemid 46333135)
18. Ghoreschi K., Gadina M., JAKpot! new small molecules in autoimmune and inflammatory diseases. Experimental Dermatology 2014 23 1 7 11
19. Ortiz-Ibanez K., Alsina M. M., Munoz-Santos C., Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermo- Sifiliográficas 2013 104 4 304 310
20. Rawlings J. S., Rosler K. M., Harrison D. A., The JAK/STAT signaling pathway. Journal of Cell Science 2004 117 8 1281 1283 2-s2.0-2342445635 10.1242/jcs.00963 (Pubitemid 38559804)
21. Ghoreschi K., Laurence A., O'Shea J. J., Janus kinases in immune cell signaling. Immunological Reviews 2009 228 1 273 287 2-s2.0-61849086101 10.1111/j.1600-065X.2008.00754.x
22. Li D.-Q., Chen Z., Song X. J., Luo L., Pflugfelder S. C., Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Investigative Ophthalmology and Visual Science 2004 45 12 4302 4311 2-s2.0-9444230614 10.1167/iovs.04-0299 (Pubitemid 39564654)
23. Meyer D. M., Jesson M. I., Li X., Elrick M. M., Funckes-Shippy C. L., Warner J. D., Gross C. J., Dowty M. E., Ramaiah S. K., Hirsch J. L., Saabye M. J., Barks J. L., Kishore N., Morris D. L., Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. Journal of Inflammation 2010 7, article 41 2-s2.0-77955375143 10.1186/1476-9255-7-41
24. O'Sullivan L. A., Liongue C., Lewis R. S., Stephenson S. E. M., Ward A. C., Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Molecular Immunology 2007 44 10 2497 2506 2-s2.0-33846903838 10.1016/j.molimm.2006.11.025 (Pubitemid 46240311)
25. Pesu M., Laurence A., Kishore N., Zwillich S. H., Chan G., O'Shea J. J., Therapeutic targeting of Janus kinases. Immunological Reviews 2008 223 1 132 142 2-s2.0-47249157224 10.1111/j.1600-065X.2008.00644.x (Pubitemid 351986189)
26. O'Shea J. J., Targeting the Jak/STAT pathway for immunosuppression. Annals of the Rheumatic Diseases 2004 63 supplement 2 ii67 ii71 2-s2.0-7044272247 10.1136/ard.2004.028290 (Pubitemid 39424662)
27. Ghoreschi K., Jesson M. I., Li X., Lee J. L., Ghosh S., Alsup J. W., Warner J. D., Tanaka M., Steward-Tharp S. M., Gadina M., Thomas C. J., Minnerly J. C., Storer C. E., LaBranche T. P., Radi Z. A., Dowty M. E., Head R. D., Meyer D. M., Kishore N., O'Shea J. J., Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). Journal of Immunology 2011 186 7 4234 4243 2-s2.0-79955027327 10.4049/jimmunol.1003668
28. Ruckert R., Asadullah K., Seifert M., Budagian V. M., Arnold R., Trombotto C., Paus R., Bulfone-Paus S., Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? Journal of Immunology 2000 165 4 2240 2250 2-s2.0-0034663951 (Pubitemid 30643174)
29. Chen Z., O'Shea J. J., Th17 cells: a new fate for differentiating helper T cells. Immunologic Research 2008 41 2 87 102 2-s2.0-44049100797 10.1007/s12026-007-8014-9
30. Fridman J. S., Scherle P. A., Collins R., Burn T., Neilan C. L., Hertel D., Contel N., Haley P., Thomas B., Shi J., Collier P., Rodgers J. D., Shepard S., Metcalf B., Hollis G., Newton R. C., Yeleswaram S., Friedman S. M., Vaddi K., Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. Journal of Investigative Dermatology 2011 131 9 1838 1844 2-s2.0-80051788025 10.1038/jid.2011.140
31. Goodman W. A., Levine A. D., Massari J. V., Sugiyama H., McCormick T. S., Cooper K. D., IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. Journal of Immunology 2009 183 5 3170 3176 2-s2.0-70349241839 10.4049/jimmunol.0803721
32. Nickoloff B. J., Xin H., Nestle F. O., Qin J.-Z., The cytokine and chemokine network in psoriasis. Clinics in Dermatology 2007 25 6 568 573 2-s2.0-36148992962 10.1016/j.clindermatol.2007.08.011 (Pubitemid 350103656)
33. Boy M. G., Wang C., Wilkinson B. E., Chow V. F.-S., Clucas A. T., Krueger J. G., Gaweco A. S., Zwillich S. H., Changelian P. S., Chan G., Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. Journal of Investigative Dermatology 2009 129 9 2299 2302 2-s2.0-70349736206 10.1038/jid.2009.25
34. Papp K. A., Menter A., Strober B., Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. British Journal of Dermatology 2012 167 3 668 677
35. Ports W. C., Khan S., Lan S., A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. British Journal of Dermatology 2013 169 1 137 145
36. Mamolo C., Harness J., Tan H., Menter A., Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology 2014 28 2 129 203
37. Tan H., Gupta P., Harness J., Dose response and pharmacokinetics of tofacitinib (CP-690, 550), an oral janus kinase inhibitor, in the treatment of chronic plaque psoriasis. CPT: Pharmacometrics & Systems Pharmacology 2013 2 e44
38. Strober B., Buonanno M., Clark J. D., Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. British Journal of Dermatology 2013 169 5 992 999
39. Tofacitinib. Drugs R D 2010 10 4 271 284
40. Punwani N., Scherle P., Flores R., Shi J., Liang J., Yeleswaram S., Levy R., Williams W., Gottlieb A., Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. Journal of the American Academy of Dermatology 2012 67 4 658 664 2-s2.0-84856053384 10.1016/j.jaad.2011.12.018
41. Maiga M., Lun S., Guo H., Winglee K., Ammerman N. C., Bishai W. R., Risk of tuberculosis reactivation with tofacitinib (CP-690550). The Journal of Infectious Diseases 2012 205 11 1705 1708
42. Burmester G. R., Blanco R., Charles-Schoeman C., Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet 2013 381 9865 451 460
43. Fleischmann R., Cutolo M., Genovese M. C., Lee E. B., Kanik K. S., Sadis S., Connell C. A., Gruben D., Krishnaswami S., Wallenstein G., Wilkinson B. E., Zwillich S. H., Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis and Rheumatism 2012 64 3 617 629 2-s2.0-84857761516 10.1002/art.33383
44. Fleischmann R., Kremer J., Cush J., Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. The New England Journal of Medicine 2012 367 6 495 507
45. Fox D. A., Kinase inhibition-a new approach to the treatment of rheumatoid arthritis. The New England Journal of Medicine 2012 367 6 565 567
46. Kremer J., Li Z. G., Hall S., Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2013 159 4 253 261
47. Kremer J. M., Cohen S., Wilkinson B. E., A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatology 2012 64 4 970 981
48. Sandborn W. J., Ghosh S., Panes J., Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. The New England Journal of Medicine 2012 367 7 616 624
49. van der Heijde D., Tanaka Y., Fleischmann R., Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and Rheumatism 2013 65 3 559 570
50. van Vollenhoven R. F., Fleischmann R., Cohen S., Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. The New England Journal of Medicine 2012 367 6 508 519
51. Scallon B. J., Moore M. A., Trinh H., Knight D. M., Ghrayeb J., Chimeric anti-TNF- α monoclonal antibody cA2 binds recombinant transmembrane TNF- α and activates immune effector functions. Cytokine 1995 7 3 251 259 2-s2.0-0029004771 10.1006/cyto.1995.0029